[Skip to nav](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#menu-mobile) [Skip to content](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#main-content)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/jeffrey-lancet/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/jeffrey-lancet/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate") Search
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
    * [ Cancers ](https://www.moffitt.org/cancers/)
      * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
      * [Acute Myelogenous Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myelogenous Leukemia \(AML\)")
      * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
      * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
      * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
      * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
      * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
      * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
      * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
      * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
      * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
      * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
      * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
      * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
      * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
      * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
      * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
      * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
      * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
      * [Chronic Myelogenous Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myelogenous Leukemia \(CML\)")
      * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
      * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
      * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
      * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
      * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
      * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
      * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
      * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
      * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
      * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
      * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
      * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
      * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
      * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
      * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
      * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
      * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
      * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
      * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
      * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
      * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
      * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
      * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
      * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
      * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
      * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
      * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
      * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
      * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
      * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
      * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
      * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
      * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
      * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
      * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
      * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
      * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
      * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
      * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
      * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
      * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
      * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
      * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
      * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
      * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
      * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
      * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
      * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
      * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
      * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
      * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
      * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
      * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
      * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
      * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
      * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
      * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
      * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
      * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
      * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
      * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")
    * [ Treatments ](https://www.moffitt.org/treatments/)
      * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
      * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
      * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
      * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
      * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
      * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
      * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
      * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
      * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
      * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
      * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
      * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
      * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
      * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
      * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
      * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
      * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
      * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
      * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
      * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
      * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
      * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")
    * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
      * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
      * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
      * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
      * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
      * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
      * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")
    * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/)
      * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
      * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
      * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
      * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
      * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
      * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")
    * [ ![](https://www.moffitt.org/contentassets/5f17f2115eca48a1aa7faa610608f778/clinical-trials.jpg) Search Clinical Trials  Moffitt participates in over 400 clinical trials. Find a trial that is right for you. ](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Search Clinical Trials")
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
    * [ Patient & Family ](https://www.moffitt.org/patient-family/)
    * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/)
      * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
      * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
      * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
      * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
      * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
      * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
      * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
      * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
      * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
      * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
      * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
      * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
      * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")
    * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/)
      * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
      * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
      * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
      * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
      * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
      * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
      * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
      * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
      * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
      * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")
    * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/)
      * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
      * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
      * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
      * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
      * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
      * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
      * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
      * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
      * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")
    * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/)
      * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
      * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
      * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
      * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
      * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
      * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
    * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/)
      * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")
    * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/)
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
      * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
      * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
      * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")
    * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/)
      * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
      * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
      * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
      * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")
    * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/)
      * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
      * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
      * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
      * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
      * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
      * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
      * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
      * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
      * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
      * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
      * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
      * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
      * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
      * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
      * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
      * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
      * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
      * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
      * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
      * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
      * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
      * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
      * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
      * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
      * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
      * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
      * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
      * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
      * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
      * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
      * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
      * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
      * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
      * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
      * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
      * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
      * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
      * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
      * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
      * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
      * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
      * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
      * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
      * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
      * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
      * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
      * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
      * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
      * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
      * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
      * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
      * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
      * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
      * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
      * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
      * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
      * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
      * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
      * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
      * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
      * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
      * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
      * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
      * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
      * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
      * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
      * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
      * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
      * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
      * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
      * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
      * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
      * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
      * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
      * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
      * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
      * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
      * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
      * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
      * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
      * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
      * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
      * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
      * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
      * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
      * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
      * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
      * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
      * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
      * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
      * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
      * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
      * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
      * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
      * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
      * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
      * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
      * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
      * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
      * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
      * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
      * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
      * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
      * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
      * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
      * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
      * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
      * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
      * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
      * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")
    * [ ![Friends supporting woman with cancer ](https://www.moffitt.org/globalassets/images/content-images/patient--family/women-cancer-640.jpg) Taking Care of Your Health  Taking Care of Your Health features cancer-related information, health tips, patient stories and more. ](https://www.moffitt.org/taking-care-of-your-health/ "Taking Care of Your Health")
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
    * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
    * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/)
      * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
      * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
      * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
      * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
      * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
      * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
      * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
      * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
      * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
      * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
      * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
      * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
      * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
      * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
      * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
      * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
      * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
      * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
      * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
      * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
      * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
      * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
      * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
      * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
      * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
      * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")
    * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
    * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/)
      * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
      * [Multidisciplinary Programs](https://www.moffitt.org/for-healthcare-professionals/continuing-education/multidisciplinary-programs/ "Multidisciplinary Programs")
      * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")
  * [Research](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
    * [ Research Science ](https://www.moffitt.org/research-science/)
    * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/)
      * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
      * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
      * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
      * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
      * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")
    * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/)
      * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
      * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
      * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
      * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
      * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")
    * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/)
      * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
      * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")
    * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/)
      * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
      * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
      * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
      * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
      * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
      * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
      * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")
    * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/)
      * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
      * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
      * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
      * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
      * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
      * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
      * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
      * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
      * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
      * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
      * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
      * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
      * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")
    * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/)
      * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
      * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")
    * [ Administration ](https://www.moffitt.org/research-science/administration/)
      * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")
    * [ ![Research fellows in a lab](https://www.moffitt.org/contentassets/a7d26515856847ad8ebe488477e34948/research-training.jpg) Research Education and Training  We are interested in recruiting scholars who have a profound interest in preventing, treating and curing cancer. ](https://www.moffitt.org/education/research-education-and-training/ "Research Education and Training")
  * [Training & Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
    * [ Education ](https://www.moffitt.org/education/)
    * [ Medical Education ](https://www.moffitt.org/education/medical-education/)
      * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
      * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
      * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
    * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/)
      * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
      * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
      * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
      * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
      * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
      * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
      * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
      * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")
    * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/)
      * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
      * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
      * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
      * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
      * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")
    * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/)
      * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
      * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
      * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
      * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
      * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
      * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
      * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
      * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
      * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
      * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
      * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
      * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
      * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
      * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
      * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
      * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
      * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
      * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
      * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
      * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
      * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
      * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
      * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
      * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")
    * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)
  * [Give](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
    * [ Give ](https://www.moffitt.org/give/)
    * [ Why Give? ](https://www.moffitt.org/give/why-give/)
      * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
      * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
      * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
      * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
      * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
      * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")
    * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/)
      * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
      * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
      * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
      * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
      * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
      * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
      * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
      * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
      * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
      * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")
    * [ Get Involved ](https://www.moffitt.org/give/get-involved/)
      * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
      * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
      * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
      * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
      * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
      * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
      * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")
    * [ ![A researcher holds a Moffitt License Plate](https://www.moffitt.org/contentassets/fff003985b6341a8b2d684da79916350/ways-to-give.jpg) Ways to Give  Cancer touches all of us. Our mission - to contribute to the prevention and cure of cancer - depends on your support.  ](https://www.moffitt.org/give/ways-to-give/ "Ways to Give")


# Jeffrey Lancet, MD
![Jeffrey  Lancet](https://www.moffitt.org/globalassets/images/researchers_bio/LancetJeffrey_3177.jpg)
Jeffrey Lancet, MD 
Program Lead, Malignant Hematology 
Research Department Chair, Malignant Hematology 
Chair, Department of Malignant Hematology
**Specialty:** Internal Medicine 
**Program:** Malignant Hematology 
**Research Program:** Molecular Medicine Program 
[ Contact ](https://eforms.moffitt.org/ContactResearchersForm?PERID=3177)
  * ## Overview
Dr. Lancet is nationally and internationally recognized for his clinical research in the field of acute leukemias, where he has developed a special interest in the design and conduct of early phase clinical trials in acute myeloid leukemia and related malignancies. 
### Associations
    * Malignant Hematology
    * Drug Discovery
    * Molecular Medicine Program
    * Experimental Therapeutics Program
### Education & Training
**Internship:**
    * Strong Memorial Hospital, Rochester School of Medicine & Dentistry - Intern
**Board Certification:**
    * Internal Medicine - Hematology
**Fellowship:**
    * Rochester School of Medicine & Dentistry - Hematology/Oncology
**Residency:**
    * Strong Memorial Hospital, Rochester School of Medicine & Dentistry - Internal Medicine
    * St. Mary's Hospital, Rochester School of Medicine & Dentistry - Chief Resident & Instructor in Medicine
**Medical School:**
    * SUNY Upstate Medical College - MD
  * ## Research Interest
Dr. Lancet’s work on novel therapies in AML, including soon to be approved drugs such as CPX-351 and Vosaroxin, has been published extensively in high-level journals. He also has a special interest in the treatment of older adults with leukemia, and is the clinical leader and co-investigator on a large National Cancer Institute grant that focuses on treatment decision models for these patients. Dr. Lancet has received funding for his clinical trials through the National Cancer Institute and industry sponsors. In addition, Dr. Lancet was one of the original recipients of the prestigious National Cancer Institute Clinical Investigator Team Leadership Award.
  * ## Participating Trials
[ Clinical Trial 23556 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23556/ "Clinical Trial 23556")   
A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents   
Condition: Malignant Hematology   
Status: Open 
**If you believe you are eligible for one of these trials or studies, please call  
[813-745-6100](tel:+813-745-6100) or toll-free [1-800-679-0775](tel:+1-800-679-0775). **
  * ## Publications
    * Aguirre LE, Ball S, Jain A, Ali NA, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clin Lymphoma Myeloma Leuk. 2025 Sep.25(9):661-671. Pubmedid: [40254502](https://www.ncbi.nlm.nih.gov/pubmed/40254502). 
    * Ball S, Jain AG, Al Ali N, Aguirre LE, Bewersdorf JP, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda DM, Padron E, Sweet K, Sallman DA, Lancet J, Carraway HE, Watts J, Zeidan A, Pollyea DA, Komrokji RS. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. Am J Hematol. 2025 Oct.100(10):1920-1923. Pubmedid: [40772639](https://www.ncbi.nlm.nih.gov/pubmed/40772639). 
    * Xie Z, Al Ali N, Zhang L, Papenhausen P, Volpe VO, Chan O, Kuykendall A, Yun S, Walker A, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji RS. Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. Blood Neoplasia. 2025 May.2(2):100062. Pubmedid: [40453136](https://www.ncbi.nlm.nih.gov/pubmed/40453136). Pmcid: PMC12067887. 
    * Komrokji Z, Ali NA, Xie Z, Chan O, Yun S, Walker A, Lancet J, Kuykendall A, Sallman D, Padron E, Komrokji RS. Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML). Leuk Res. 2025 Mar.150:107662. Pubmedid: [39921921](https://www.ncbi.nlm.nih.gov/pubmed/39921921). 
    * Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahmé R, Winer ES, Lehmann-Che J, Roboz GJ, Madelaine I, Sekeres MA, Peterlin P, Chan O, Beyne-Rauzy O, Kuykendall A, Recher C, McLemore A, Stamatoullas A, Zhang L, Willems L, Mo Q, Raffoux E, Nardelli L, Berthon C, Al Ali NH, Quesnel B, Padron E, Kantarjian HM, List AF, Ades L, Lancet JE, Fenaux P, Cluzeau T. Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. Hemasphere. 2025 Jul.9(7):e70164. Pubmedid: [40657305](https://www.ncbi.nlm.nih.gov/pubmed/40657305). Pmcid: PMC12255903. 
    * Komrokji RS, Ammad-Ud-Din M, Ali NHA, Xie Z, Chan O, Kuykendall AT, Yun S, Walker AR, Lancet J, Padron E, Sallman DA. Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival. Clin Lymphoma Myeloma Leuk. 2025 Jul.25(7):e487-e490. Pubmedid: [40113545](https://www.ncbi.nlm.nih.gov/pubmed/40113545). 
    * Jain AG, Volpe VO, Wang C, Ball S, Tobon K, Chan O, Padron E, Kuykendall A, Lancet JE, Komrokji R, Sallman DA, Sweet KL. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Ann Hematol. 2025 Jan.104(1):307-315. Pubmedid: [39243312](https://www.ncbi.nlm.nih.gov/pubmed/39243312). 
    * Consagra A, Lanino L, Al Ali NH, Aguirre L, Xie Z, Chan O, Andreossi G, Raddi MG, Rigodanza L, Sanna A, Mattiuz G, Tofacchi E, Amato C, Tanturli M, De Pourcq S, Walker A, Kuykendall A, Lancet J, Padron E, Sallman DA, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Maggioni G, Campagna A, Della Porta MG, Santini V, Komrokji RS. Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS. Hemasphere. 2025 Feb.9(2):e70086. Pubmedid: [39944234](https://www.ncbi.nlm.nih.gov/pubmed/39944234). Pmcid: PMC11814532. 
    * Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol. 2024 Oct.99(10):1870-1876. Pubmedid: [38899566](https://www.ncbi.nlm.nih.gov/pubmed/38899566). 
    * Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, Mishra A, Sweet K, Perez L, Ochoa-Bayona J, Nieder M, Komrokji R, Lancet J, Fernandez H, Nishihori T, Pidala J, Anasetti C, Bejanyan N. Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Transplant Cell Ther. 2024 Nov.30(11):1090.e1-1090.e10. Pubmedid: [39147136](https://www.ncbi.nlm.nih.gov/pubmed/39147136). 
    * Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024 Nov.11(11):e862-e872. Pubmedid: [39393368](https://www.ncbi.nlm.nih.gov/pubmed/39393368). 
    * Chan O, Al Ali NH, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini MO, Song J, Yun S, Talati C, Kuykendall AT, Padron E, Walker AR, Roboz GJ, Desai P, Sallman DA, Sweet KL, Komrokji RS, Lancet JE. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024 Mar.8(5):1075-1083. Pubmedid: [38170740](https://www.ncbi.nlm.nih.gov/pubmed/38170740). Pmcid: PMC10907389. 
    * Jain AG, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman DA, Lancet JE, Pinilla-Ibarz J, Sweet K. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Ann Hematol. 2024 Jun.103(6):1941-1945. Pubmedid: [38634915](https://www.ncbi.nlm.nih.gov/pubmed/38634915). Pmcid: PMC11090947. 
    * Chavez JC, Grajales A, Sandoval-Sus J, Turba E, Nodzon L, Uriepero-Palma A, Ammad-Ud-Din M, Sahakian E, Komrokji R, Sokol L, Locke FL, Shah B, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Bello C, Pinilla-Ibarz J. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):382-391.e2. Pubmedid: [38508880](https://www.ncbi.nlm.nih.gov/pubmed/38508880). 
    * Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):400-406. Pubmedid: [38429222](https://www.ncbi.nlm.nih.gov/pubmed/38429222). 
    * Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024 Jul.109(7):2157-2164. Pubmedid: [38299605](https://www.ncbi.nlm.nih.gov/pubmed/38299605). Pmcid: PMC11215361. 
    * Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clin Lymphoma Myeloma Leuk. 2024 Jul.24(7):459-467. Pubmedid: [38548563](https://www.ncbi.nlm.nih.gov/pubmed/38548563). 
    * Horvat NP, Abdallah EF, Xie Z, Al Ali N, Yun S, Walker A, Padron E, Sallman D, Chan O, Lancet J, Komrokji R, Kuykendall AT. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024 Jan.103(1):117-123. Pubmedid: [38030891](https://www.ncbi.nlm.nih.gov/pubmed/38030891). 
    * Tinsley-Vance SM, Lancet JE. First, do no harm: quality over quantity?. Blood. 2024 Aug.144(5):471-472. Pubmedid: [39088225](https://www.ncbi.nlm.nih.gov/pubmed/39088225). Pmcid: PMC11406179. 
    * Jain AG, Ball S, Aguirre LE, Tobon KA, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet JE, Sweet K. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):e315-e322. Pubmedid: [37558530](https://www.ncbi.nlm.nih.gov/pubmed/37558530). 
    * Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2023 May.21(5):503-513. Pubmedid: [37156478](https://www.ncbi.nlm.nih.gov/pubmed/37156478). 
    * Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 May.41(15):2815-2826. Pubmedid: [36888930](https://www.ncbi.nlm.nih.gov/pubmed/36888930). 
    * Tinsley-Vance SM, Ali NA, Ball S, Aguirre LE, Jain AG, Hussaini MO, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman DA, Komrokji RS. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clin Lymphoma Myeloma Leuk. 2023 May.23(5):355-359. Pubmedid: [36813626](https://www.ncbi.nlm.nih.gov/pubmed/36813626). Pmcid: PMC10121764. 
    * Mo Q, Yun S, Sallman DA, Vincelette ND, Peng G, Zhang L, Lancet JE, Padron E. Integrative molecular subtypes of acute myeloid leukemia. Blood Cancer J. 2023 May.13(1):71. Pubmedid: [37156780](https://www.ncbi.nlm.nih.gov/pubmed/37156780). Pmcid: PMC10167212. 
    * Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: [36624015](https://www.ncbi.nlm.nih.gov/pubmed/36624015). 
    * Shafer D, Kagan AB, Rudek MA, Kmieciak M, Tombes MB, Shrader E, Bandyopadhyay D, Hudson D, Sankala H, Weir C, Lancet JE, Grant S. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemother Pharmacol. 2023 Mar.91(3):281-290. Pubmedid: [36864346](https://www.ncbi.nlm.nih.gov/pubmed/36864346). 
    * Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. Hum Pathol. 2023 Jun.136:1-15. Pubmedid: [36958463](https://www.ncbi.nlm.nih.gov/pubmed/36958463). 
    * Komrokji RS, Aguirre LE, Al-Ali N, Chan O, Xie Z, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Sallman DA. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Adv. 2023 Jul.7(14):3677-3679. Pubmedid: [37058483](https://www.ncbi.nlm.nih.gov/pubmed/37058483). Pmcid: PMC10365940. 
    * Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J. Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients. Cancer Commun (Lond). 2023 Jul.43(7):749-764. Pubmedid: [37377402](https://www.ncbi.nlm.nih.gov/pubmed/37377402). Pmcid: PMC10354405. 
    * Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, Tinsley-Vance SM, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023 Jul.37(7):1530-1539. Pubmedid: [37147425](https://www.ncbi.nlm.nih.gov/pubmed/37147425). 
    * Ball S, Aguirre LE, Jain AG, Ali NA, Tinsley SM, Chan O, Kuykendall AT, Sweet K, Lancet JE, Sallman DA, Hussaini MO, Padron E, Komrokji RS. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leuk Res. 2023 Jan.124:106999. Pubmedid: [36542963](https://www.ncbi.nlm.nih.gov/pubmed/36542963). 
    * Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 Feb.141(6):567-578. Pubmedid: [36399715](https://www.ncbi.nlm.nih.gov/pubmed/36399715). 
    * Patel PC, Ball S, Jain AG, Wang C, Hussaini MO, Aguirre LE, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet JE, Komrokji RS, Sallman DA. Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. Am J Hematol. 2023 Dec.98(12):E360-E363. Pubmedid: [37705256](https://www.ncbi.nlm.nih.gov/pubmed/37705256). 
    * Dukes CW, Potez M, Lancet J, Kuter BJ, Whiting J, Mo Q, Leav B, Wang H, Vanas JS, Cubitt CL, Isaacs-Soriano K, Kennedy K, Rathwell J, Diaz Cobo J, O'Nan W, Sirak B, Dong N, Tan E, Hwu P, Giuliano AR, Pilon-Thomas S. Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients. Vaccines (Basel). 2023 Dec.12(1). Pubmedid: [38250826](https://www.ncbi.nlm.nih.gov/pubmed/38250826). Pmcid: PMC10818923. 
    * Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. Clin Cancer Res. 2023 Aug.29(15):2919-2932. Pubmedid: [37223910](https://www.ncbi.nlm.nih.gov/pubmed/37223910). Pmcid: PMC10524644. 
    * Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr.10(4):e272-e283. Pubmedid: [36990622](https://www.ncbi.nlm.nih.gov/pubmed/36990622). 
    * Komrokji R, Al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. Haematologica. 2023 Apr.108(4):1168-1172. Pubmedid: [36420802](https://www.ncbi.nlm.nih.gov/pubmed/36420802). Pmcid: PMC10071110. 
    * Uy GL, Newell LF, Lin TL, Goldberg SL, Wieduwilt MJ, Ryan RJ, Faderl S, Lancet JE. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022 Sep.6(17):4989-4993. Pubmedid: [35443022](https://www.ncbi.nlm.nih.gov/pubmed/35443022). Pmcid: PMC9631647. 
    * Kuykendall AT, Mo Q, Sallman DA, Ali NA, Chan O, Yun S, Sweet KL, Padron E, Lancet JE, Komrokji RS. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022 Oct.128(19):3495-3501. Pubmedid: [35942592](https://www.ncbi.nlm.nih.gov/pubmed/35942592). 
    * Cortes JE, Lin TL, Asubonteng K, Faderl S, Lancet JE, Prebet T. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022 Oct.15(1):155. Pubmedid: [36289532](https://www.ncbi.nlm.nih.gov/pubmed/36289532). Pmcid: PMC9598030. 
    * Lee D, Jain AG, Deutsch Y, Eatrides J, Chan O, Padron E, Kuykendall A, Komrokji R, Lancet J, Sallman D, Talati C, Sweet K. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):774-779. Pubmedid: [35760672](https://www.ncbi.nlm.nih.gov/pubmed/35760672). 
    * Bradley T, Kwon D, Monge J, Sekeres M, Chandhok N, Thomassen A, Swords R, Padron E, Lancet J, Talati C, Watts J. Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia. EJHaem. 2022 Nov.3(4):1231-1240. Pubmedid: [36467830](https://www.ncbi.nlm.nih.gov/pubmed/36467830). Pmcid: PMC9713060. 
    * Komrokji RS, Singh AM, Ali NA, Chan O, Padron E, Sweet K, Kuykendall A, Lancet JE, Sallman DA. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022 Nov.12(11):148. Pubmedid: [36329025](https://www.ncbi.nlm.nih.gov/pubmed/36329025). Pmcid: PMC9633639. 
    * Ball S, Knepper TC, Deutsch YE, Samra W, Watts JM, Bradley TJ, Chan O, Hussaini MO, Zhang L, Sweet KL, Kuykendall AT, Talati C, Padron E, Komrokji RS, Lancet JE, Sallman DA. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022 Nov.128(21):3880-3887. Pubmedid: [36107670](https://www.ncbi.nlm.nih.gov/pubmed/36107670). 
    * Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022 May.8(5):748-754. Pubmedid: [35266953](https://www.ncbi.nlm.nih.gov/pubmed/35266953). Pmcid: PMC8914884. 
    * Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, Kuykendall AT, Sweet KL, Lancet JE, Swoboda DM, Padron E, Komrokji RS, Sallman DA. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022 May.97(5):E185-E188. Pubmedid: [35179241](https://www.ncbi.nlm.nih.gov/pubmed/35179241). 
    * Ravandi F, Lancet J. Is acute myeloid leukaemia maintenance therapy necessary?. Lancet Haematol. 2022 Mar.9(3):e177-e178. Pubmedid: [35240073](https://www.ncbi.nlm.nih.gov/pubmed/35240073). 
    * Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. 2022 Mar.107(3):737-739. Pubmedid: [34320786](https://www.ncbi.nlm.nih.gov/pubmed/34320786). Pmcid: PMC8883562. 
    * Castillo Tokumori F, Al Ali N, Chan O, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e521-e525. Pubmedid: [35241387](https://www.ncbi.nlm.nih.gov/pubmed/35241387). 
    * Chan O, Ali NA, Sallman D, Padron E, Lancet J, Komrokji R. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e467-e476. Pubmedid: [35101379](https://www.ncbi.nlm.nih.gov/pubmed/35101379). 
    * Volpe VO, Al Ali N, Chan O, Padron E, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Komrokji RS. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. Brit J Haematol. 2022 Aug.198(4):713-720. Pubmedid: [35751140](https://www.ncbi.nlm.nih.gov/pubmed/35751140). 
    * Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, Sallman DA, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res. 2021 Oct.109:106640. Pubmedid: [34144312](https://www.ncbi.nlm.nih.gov/pubmed/34144312). 
    * Hunter AM, Newman H, DeZern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res. 2021 Nov.27(22):6095-6105. Pubmedid: [34253584](https://www.ncbi.nlm.nih.gov/pubmed/34253584). Pmcid: PMC8595542. 
    * Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leuk Lymphoma. 2021 Nov.62(11):2762-2767. Pubmedid: [34114922](https://www.ncbi.nlm.nih.gov/pubmed/34114922). 
    * Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: [33449813](https://www.ncbi.nlm.nih.gov/pubmed/33449813). Pmcid: PMC8099410. 
    * Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: [33781526](https://www.ncbi.nlm.nih.gov/pubmed/33781526). Pmcid: PMC8711732. 
    * Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 Mar.5(6):1719-1728. Pubmedid: [33724305](https://www.ncbi.nlm.nih.gov/pubmed/33724305). Pmcid: PMC7993093. 
    * Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Jun.21(6):421-424.e2. Pubmedid: [33583730](https://www.ncbi.nlm.nih.gov/pubmed/33583730). 
    * Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul.8(7):e481-e491. Pubmedid: [34171279](https://www.ncbi.nlm.nih.gov/pubmed/34171279). 
    * Cortes JE, Lin TL, Uy GL, Ryan RJ, Faderl S, Lancet JE. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 Jul.14(1):110. Pubmedid: [34256819](https://www.ncbi.nlm.nih.gov/pubmed/34256819). Pmcid: PMC8276472. 
    * Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021 Jan.35(1):286-288. Pubmedid: [33132383](https://www.ncbi.nlm.nih.gov/pubmed/33132383). 
    * Schwabkey ZI, Al Ali N, Chan O, Sallman DA, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e52-e56. Pubmedid: [33093008](https://www.ncbi.nlm.nih.gov/pubmed/33093008). 
    * Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Ne. 2021 Jan.19(1):16-27. Pubmedid: [33406488](https://www.ncbi.nlm.nih.gov/pubmed/33406488). 
    * Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: [33591325](https://www.ncbi.nlm.nih.gov/pubmed/33591325). Pmcid: PMC7903224. 
    * Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. MYC overexpression is associated with an early disease progression from MDS to AML. Leuk Res. 2021 Dec.111:106733. Pubmedid: [34749168](https://www.ncbi.nlm.nih.gov/pubmed/34749168). Pmcid: PMC8643343. 
    * Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec.26(1):393-397. Pubmedid: [34029507](https://www.ncbi.nlm.nih.gov/pubmed/34029507). 
    * Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021 Apr.35(4):1145-1155. Pubmedid: [32728186](https://www.ncbi.nlm.nih.gov/pubmed/32728186). Pmcid: PMC7854836. 
    * Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 Sep.20(9):e597-e605. Pubmedid: [32303488](https://www.ncbi.nlm.nih.gov/pubmed/32303488). 
    * Reljic T, Sehovic M, Lancet J, Kim J, Al Ali N, Djulbegovic B, Extermann M. Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. Geriatr Oncol. 2020 Nov.11(8):1293-1308. Pubmedid: [32665186](https://www.ncbi.nlm.nih.gov/pubmed/32665186). Pmcid: PMC7864384. 
    * Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020 Nov.34(11):3097-3099. Pubmedid: [32565544](https://www.ncbi.nlm.nih.gov/pubmed/32565544). 
    * Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):324-328. Pubmedid: [32044274](https://www.ncbi.nlm.nih.gov/pubmed/32044274). 
    * Melody M, Kuykendall A, Sallman D, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):312-315. Pubmedid: [32139296](https://www.ncbi.nlm.nih.gov/pubmed/32139296). 
    * Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clin Pharmacol Ther. 2020 Mar.107(3):563-570. Pubmedid: [31549389](https://www.ncbi.nlm.nih.gov/pubmed/31549389). Pmcid: PMC7018540. 
    * Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 Mar.61(3):631-640. Pubmedid: [31760835](https://www.ncbi.nlm.nih.gov/pubmed/31760835). 
    * Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, Sallman DA, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Leuk Lymphoma. 2020 Jun.61(6):1395-1405. Pubmedid: [32091281](https://www.ncbi.nlm.nih.gov/pubmed/32091281). Pmcid: PMC7269833. 
    * Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020 Jun.93:106367. Pubmedid: [32408060](https://www.ncbi.nlm.nih.gov/pubmed/32408060). Pmcid: PMC7771257. 
    * Badar T, Szabo A, Sallman D, Komrokji R, Lancet J, Padron E, Song J, Hussaini MO. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020 Jun.61(6):1418-1427. Pubmedid: [32013644](https://www.ncbi.nlm.nih.gov/pubmed/32013644). 
    * Asghari H, Lancet J. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Jun.61(6):1305-1312. Pubmedid: [32037927](https://www.ncbi.nlm.nih.gov/pubmed/32037927). 
    * Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 Jun.20(6):400-406.e2. Pubmedid: [32179032](https://www.ncbi.nlm.nih.gov/pubmed/32179032). Pmcid: PMC7771378. 
    * Yun S, Chan O, Kerr D, Vincelette ND, Idrees A, Mo Q, Sweet K, Lancet JE, Kharfan-Dabaja MA, Zhang L, Sokol L. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv. 2020 Jul.4(14):3435-3442. Pubmedid: [32722779](https://www.ncbi.nlm.nih.gov/pubmed/32722779). Pmcid: PMC7391135. 
    * Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica. 2020 Jan.105(2):398-406. Pubmedid: [31073071](https://www.ncbi.nlm.nih.gov/pubmed/31073071). Pmcid: PMC7012500. 
    * Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2020 Jan.26(1):54-60. Pubmedid: [31636097](https://www.ncbi.nlm.nih.gov/pubmed/31636097). Pmcid: PMC7787346. 
    * Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: [32730593](https://www.ncbi.nlm.nih.gov/pubmed/32730593). Pmcid: PMC7731792. 
    * Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: [32778513](https://www.ncbi.nlm.nih.gov/pubmed/32778513). 
    * Duong VH, Al Ali N, Zhang L, Padron E, Sallman D, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Leuk Lymphoma. 2020 Aug.61(8):1901-1907. Pubmedid: [32306798](https://www.ncbi.nlm.nih.gov/pubmed/32306798). 
    * Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, Litzow MR, Komrokji RS, Erba HP, Appelbaum FR. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020 Apr.4(8):1683-1689. Pubmedid: [32330241](https://www.ncbi.nlm.nih.gov/pubmed/32330241). Pmcid: PMC7189292. 
    * Shrestha B, Zhang Y, Yu B, Li G, Boucher JC, Beatty NJ, Tsai HC, Wang X, Mishra A, Sweet K, Lancet JE, Kelley L, Davila ML. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells. J Immunother. 2020 Apr.43(3):79-88. Pubmedid: [31834208](https://www.ncbi.nlm.nih.gov/pubmed/31834208). Pmcid: PMC7077957. 
    * Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: [31357093](https://www.ncbi.nlm.nih.gov/pubmed/31357093). Pmcid: PMC7375354. 
    * Lindsley RC, Gibson CJ, Murdock HM, Stone RM, Cortes JE, Uy GL, Lin TL, Ritchie EK, Prebet T, Ryan RJ, Faderl S, Lancet JE. Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood. 2019 Nov.134(Supplement_1):15. Pubmedid: [31723998](https://www.ncbi.nlm.nih.gov/pubmed/31723998). 
    * Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2019 Mar.19(3):157-161. Pubmedid: [30713125](https://www.ncbi.nlm.nih.gov/pubmed/30713125). 
    * Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res. 2019 Jun.81:56-61. Pubmedid: [31030089](https://www.ncbi.nlm.nih.gov/pubmed/31030089). Pmcid: PMC7787349. 
    * Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2019 Jun.17(6):721-749. Pubmedid: [31200351](https://www.ncbi.nlm.nih.gov/pubmed/31200351). 
    * Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Sci Rep. 2019 Jan.9(1):606. Pubmedid: [30679640](https://www.ncbi.nlm.nih.gov/pubmed/30679640). Pmcid: PMC6345777. 
    * Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan.94(1):87-92. Pubmedid: [30390311](https://www.ncbi.nlm.nih.gov/pubmed/30390311). 
    * McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. Brit J Haematol. 2019 Feb.184(3):450-455. Pubmedid: [29359794](https://www.ncbi.nlm.nih.gov/pubmed/29359794). Pmcid: PMC7771337. 
    * Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec.94(12):E314-E317. Pubmedid: [31444809](https://www.ncbi.nlm.nih.gov/pubmed/31444809). 
    * Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, List AF. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clin Lymphoma Myeloma Leuk. 2019 Apr.19(4):251-254. Pubmedid: [30852241](https://www.ncbi.nlm.nih.gov/pubmed/30852241). 
    * Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 Apr.380(17):1628-1637. Pubmedid: [31018069](https://www.ncbi.nlm.nih.gov/pubmed/31018069). 
    * Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018 Sep.132(11):1125-1133. Pubmedid: [30045838](https://www.ncbi.nlm.nih.gov/pubmed/30045838). Pmcid: PMC6265631. 
    * Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res. 2018 Sep.72:92-95. Pubmedid: [30118897](https://www.ncbi.nlm.nih.gov/pubmed/30118897). Pmcid: PMC7169946. 
    * Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 Sep.36(26):2684-2692. Pubmedid: [30024784](https://www.ncbi.nlm.nih.gov/pubmed/30024784). Pmcid: PMC6127025. 
    * Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 Nov.103(11):e514-e518. Pubmedid: [29794146](https://www.ncbi.nlm.nih.gov/pubmed/29794146). Pmcid: PMC6278965. 
    * Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. Am Soc Clin Oncol Educ Book. 2018 May.38:555-573. Pubmedid: [30231330](https://www.ncbi.nlm.nih.gov/pubmed/30231330). 
    * Talati C, Lancet JE. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Future Oncol. 2018 May.14(12):1147-1154. Pubmedid: [29378418](https://www.ncbi.nlm.nih.gov/pubmed/29378418). 
    * Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet JE, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 May.24(10):2294-2303. Pubmedid: [29463550](https://www.ncbi.nlm.nih.gov/pubmed/29463550). 
    * Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar.97(3):435-441. Pubmedid: [29189896](https://www.ncbi.nlm.nih.gov/pubmed/29189896). 
    * Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. Cancer Genomics Proteomics. 2018 Mar.15(2):121-126. Pubmedid: [29496691](https://www.ncbi.nlm.nih.gov/pubmed/29496691). Pmcid: PMC5892606. 
    * Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018 Jan.81(1):171-178. Pubmedid: [29167924](https://www.ncbi.nlm.nih.gov/pubmed/29167924). Pmcid: PMC5756117. 
    * Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho P, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan.131(4):387-396. Pubmedid: [29196412](https://www.ncbi.nlm.nih.gov/pubmed/29196412). Pmcid: PMC5813721. 
    * Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Ann Hematol. 2018 Feb.97(2):247-254. Pubmedid: [29167940](https://www.ncbi.nlm.nih.gov/pubmed/29167940). 
    * Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018 Feb.93(2):E49-E52. Pubmedid: [29164656](https://www.ncbi.nlm.nih.gov/pubmed/29164656). Pmcid: PMC5760282. 
    * Lancet JE. Is the overall survival for older adults with AML finally improving?. Best Pract Res Clin Haematol. 2018 Dec.31(4):387-390. Pubmedid: [30466753](https://www.ncbi.nlm.nih.gov/pubmed/30466753). 
    * Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, Komrokji R, Djeu J, List A, Wei S. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017 Oct.31(10):2172-2180. Pubmedid: [28096534](https://www.ncbi.nlm.nih.gov/pubmed/28096534). Pmcid: PMC5552472. 
    * Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Nov.15(11):1414-1427. Pubmedid: [29118233](https://www.ncbi.nlm.nih.gov/pubmed/29118233). 
    * Sweet K, Lancet J. State of the Art Update and Next Questions: Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):703-709. Pubmedid: [29110833](https://www.ncbi.nlm.nih.gov/pubmed/29110833). 
    * Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: [28687222](https://www.ncbi.nlm.nih.gov/pubmed/28687222). Pmcid: PMC5675815. 
    * Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: [28006850](https://www.ncbi.nlm.nih.gov/pubmed/28006850). 
    * Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Mar.129(13):1881-1883. Pubmedid: [28159734](https://www.ncbi.nlm.nih.gov/pubmed/28159734). 
    * Sallman DA, Lancet JE. What are the most promising new agents in acute myeloid leukemia?. Curr Opin Hematol. 2017 Mar.24(2):99-107. Pubmedid: [28030373](https://www.ncbi.nlm.nih.gov/pubmed/28030373). 
    * Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Jun.31(6):1391-1397. Pubmedid: [28111463](https://www.ncbi.nlm.nih.gov/pubmed/28111463). 
    * Tinsley SM, Sutton SK, Thapa R, Lancet J, McMillan SC. Treatment Choices: A Quality of Life Comparison in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Jul.17S:S75-S79. Pubmedid: [28760305](https://www.ncbi.nlm.nih.gov/pubmed/28760305). Pmcid: PMC7771348. 
    * O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Jul.15(7):926-957. Pubmedid: [28687581](https://www.ncbi.nlm.nih.gov/pubmed/28687581). 
    * Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan.18(1):112-121. Pubmedid: [27927582](https://www.ncbi.nlm.nih.gov/pubmed/27927582). Pmcid: PMC7771361. 
    * Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):e45-e53. Pubmedid: [28869184](https://www.ncbi.nlm.nih.gov/pubmed/28869184). 
    * Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):902-907. Pubmedid: [29030092](https://www.ncbi.nlm.nih.gov/pubmed/29030092). 
    * Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. Leuk Res. 2017 Aug.59:65. Pubmedid: [28575698](https://www.ncbi.nlm.nih.gov/pubmed/28575698). 
    * Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Apr.17(4):211-214. Pubmedid: [28185797](https://www.ncbi.nlm.nih.gov/pubmed/28185797). 
    * Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017 11.7(12):633. Pubmedid: [29176559](https://www.ncbi.nlm.nih.gov/pubmed/29176559). Pmcid: PMC5802523. 
    * Zhang X, Lancet JE, Zhang L. Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. Leuk Lymphoma. 2016 Sep.56(11):3022-3030. Pubmedid: [25927244](https://www.ncbi.nlm.nih.gov/pubmed/25927244). 
    * Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov.101(11):e457-e460. Pubmedid: [27418649](https://www.ncbi.nlm.nih.gov/pubmed/27418649). Pmcid: PMC5394875. 
    * Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016 Nov.50:123-131. Pubmedid: [27736729](https://www.ncbi.nlm.nih.gov/pubmed/27736729). 
    * Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May.91(5):E280-E283. Pubmedid: [26875020](https://www.ncbi.nlm.nih.gov/pubmed/26875020). 
    * Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar.42:52-58. Pubmedid: [26894965](https://www.ncbi.nlm.nih.gov/pubmed/26894965). 
    * Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar.30(3):666-673. Pubmedid: [26514544](https://www.ncbi.nlm.nih.gov/pubmed/26514544). Pmcid: PMC7864381. 
    * Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul.5(7):1694-1701. Pubmedid: [27098006](https://www.ncbi.nlm.nih.gov/pubmed/27098006). Pmcid: PMC4944897. 
    * Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol. 2016 Dec.136(4):210-218. Pubmedid: [27632567](https://www.ncbi.nlm.nih.gov/pubmed/27632567). Pmcid: PMC5198772. 
    * McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug.101(8):e320-e323. Pubmedid: [27081179](https://www.ncbi.nlm.nih.gov/pubmed/27081179). Pmcid: PMC4967580. 
    * Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S64-S66. Pubmedid: [27521328](https://www.ncbi.nlm.nih.gov/pubmed/27521328). 
    * Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S53-S56. Pubmedid: [27521325](https://www.ncbi.nlm.nih.gov/pubmed/27521325). 
    * Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S44-S48. Pubmedid: [27521323](https://www.ncbi.nlm.nih.gov/pubmed/27521323). 
    * Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug.47:78-83. Pubmedid: [27285853](https://www.ncbi.nlm.nih.gov/pubmed/27285853). 
    * Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016 Aug.22(15):3746-3754. Pubmedid: [26858309](https://www.ncbi.nlm.nih.gov/pubmed/26858309). Pmcid: PMC5278764. 
    * Lancet JE. FLT3 inhibitors for acute myeloid leukemia. Clin Adv Hematol Oncol. 2015 Sep.13(9):573-575. Pubmedid: [26452187](https://www.ncbi.nlm.nih.gov/pubmed/26452187). 
    * Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep.100(9):1172-1179. Pubmedid: [26022709](https://www.ncbi.nlm.nih.gov/pubmed/26022709). Pmcid: PMC4800702. 
    * Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep.16(9):1025-1036. Pubmedid: [26234174](https://www.ncbi.nlm.nih.gov/pubmed/26234174). Pmcid: PMC4822512. 
    * Griffin PT, Komrokji RS, DeCastro CM, Rizzieri DA, Melchert M, List AF, Lancet JE. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. Am J Hematol. 2015 Sep.90(9):796-799. Pubmedid: [26089240](https://www.ncbi.nlm.nih.gov/pubmed/26089240). 
    * Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015 Nov.15(11):705-710. Pubmedid: [26440749](https://www.ncbi.nlm.nih.gov/pubmed/26440749). 
    * Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar.121(6):876-882. Pubmedid: [25410759](https://www.ncbi.nlm.nih.gov/pubmed/25410759). Pmcid: PMC4378905. 
    * Garcia-Manero G, Khoury HJ, Jabbour E, Lancet JE, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, List AF, Kantarjian H, Komrokji RS. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar.21(5):985-994. Pubmedid: [25480830](https://www.ncbi.nlm.nih.gov/pubmed/25480830). Pmcid: PMC4348327. 
    * Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S60-S63. Pubmedid: [26297280](https://www.ncbi.nlm.nih.gov/pubmed/26297280). 
    * Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul.39(7):673-678. Pubmedid: [25934048](https://www.ncbi.nlm.nih.gov/pubmed/25934048). Pmcid: PMC5992898. 
    * Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul.90(7):602-607. Pubmedid: [25802083](https://www.ncbi.nlm.nih.gov/pubmed/25802083). Pmcid: PMC4617516. 
    * Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2015 Jan.39(1):6-17. Pubmedid: [25465125](https://www.ncbi.nlm.nih.gov/pubmed/25465125). 
    * Tao J, Zhang X, Lancet J, Bennett JM, Cai L, Papenhausen P, Moscinski L, Zhang L. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation. Cancer Genet. 2015 Feb.207(10-12):489-494. Pubmedid: [25453399](https://www.ncbi.nlm.nih.gov/pubmed/25453399). 
    * Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015 Feb.100(2):231-237. Pubmedid: [25381131](https://www.ncbi.nlm.nih.gov/pubmed/25381131). Pmcid: PMC4803139. 
    * Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015 Apr.133(2):249-256. Pubmedid: [25413011](https://www.ncbi.nlm.nih.gov/pubmed/25413011). 
    * Horna P, Zhang L, Sotomayor EM, Lancet JE, Moscinski LC. Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid. Am J Clin Pathol. 2014 Oct.142(4):546-552. Pubmedid: [25239423](https://www.ncbi.nlm.nih.gov/pubmed/25239423). Pmcid: PMC5744863. 
    * Lancet JE. Postremission therapy in acute promyelocytic leukemia: room for improvement?. J Clin Oncol. 2014 Nov.32(33):3692-3696. Pubmedid: [25245443](https://www.ncbi.nlm.nih.gov/pubmed/25245443). 
    * Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May.123(21):3239-3246. Pubmedid: [24687088](https://www.ncbi.nlm.nih.gov/pubmed/24687088). Pmcid: PMC4624448. 
    * Sweet K, Lancet JE. Novel therapeutics in acute myeloid leukemia. Curr Hematol Malig Rep. 2014 Jun.9(2):109-117. Pubmedid: [24633743](https://www.ncbi.nlm.nih.gov/pubmed/24633743). 
    * Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun.20(6):776-780. Pubmedid: [24534108](https://www.ncbi.nlm.nih.gov/pubmed/24534108). 
    * Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun.123(23):3675-3677. Pubmedid: [24904105](https://www.ncbi.nlm.nih.gov/pubmed/24904105). Pmcid: PMC4047502. 
    * Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec.100(6):567-574. Pubmedid: [25281405](https://www.ncbi.nlm.nih.gov/pubmed/25281405). 
    * Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug.89(8):809-812. Pubmedid: [24764152](https://www.ncbi.nlm.nih.gov/pubmed/24764152). Pmcid: PMC4561860. 
    * Horna P, Pantazopoulos P, Lancet JE, Moscinski LC, Zhang L. Prominent hematogone hyperplasia in BCR-ABL1-positive chronic myelogenous leukemia: mimicking recurrent B-lymphoid blast crisis. Leuk Lymphoma. 2014 Aug.55(8):1952-1954. Pubmedid: [24304373](https://www.ncbi.nlm.nih.gov/pubmed/24304373). 
    * Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr.38(4):443-446. Pubmedid: [24439565](https://www.ncbi.nlm.nih.gov/pubmed/24439565). 
    * O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M. Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Ne. 2013 Sep.11(9):1047-1055. Pubmedid: [24029121](https://www.ncbi.nlm.nih.gov/pubmed/24029121). Pmcid: PMC4161234. 
    * Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep.13 Suppl 2:S295-S299. Pubmedid: [24290214](https://www.ncbi.nlm.nih.gov/pubmed/24290214). 
    * Lancet JE. New agents: great expectations not realized. Best Pract Res Clin Haematol. 2013 Sep.26(3):269-274. Pubmedid: [24309529](https://www.ncbi.nlm.nih.gov/pubmed/24309529). 
    * Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Brit J Haematol. 2013 Nov.163(3):315-325. Pubmedid: [24033280](https://www.ncbi.nlm.nih.gov/pubmed/24033280). 
    * Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov.37(11):1461-1467. Pubmedid: [23993427](https://www.ncbi.nlm.nih.gov/pubmed/23993427). Pmcid: PMC4205589. 
    * Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May.37(5):510-515. Pubmedid: [23332452](https://www.ncbi.nlm.nih.gov/pubmed/23332452). 
    * Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res. 2013 Mar.37(3):300-304. Pubmedid: [23273539](https://www.ncbi.nlm.nih.gov/pubmed/23273539). 
    * Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol. 2013 Mar.20(2):100-106. Pubmedid: [23385612](https://www.ncbi.nlm.nih.gov/pubmed/23385612). 
    * Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun.121(25):5068-5077. Pubmedid: [23632888](https://www.ncbi.nlm.nih.gov/pubmed/23632888). Pmcid: PMC4347259. 
    * Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul.88(7):566-570. Pubmedid: [23605934](https://www.ncbi.nlm.nih.gov/pubmed/23605934). Pmcid: PMC4685468. 
    * Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013 Jan.98(1):119-128. Pubmedid: [22801961](https://www.ncbi.nlm.nih.gov/pubmed/22801961). Pmcid: PMC3533673. 
    * Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb.32(9):1110-1120. Pubmedid: [22525275](https://www.ncbi.nlm.nih.gov/pubmed/22525275). Pmcid: PMC3751397. 
    * Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk. 2013 Dec.13(6):711-715. Pubmedid: [24054159](https://www.ncbi.nlm.nih.gov/pubmed/24054159). 
    * Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Brit J Haematol. 2013 Aug.162(4):517-524. Pubmedid: [23789936](https://www.ncbi.nlm.nih.gov/pubmed/23789936). Pmcid: PMC4685467. 
    * Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr.21(4):1097-1103. Pubmedid: [23179489](https://www.ncbi.nlm.nih.gov/pubmed/23179489). 
    * Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct.120(17):3419-3424. Pubmedid: [22936658](https://www.ncbi.nlm.nih.gov/pubmed/22936658). 
    * Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, Mayer LD, Louie AC, Lancet JE. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012 Oct.36(10):1283-1289. Pubmedid: [22840315](https://www.ncbi.nlm.nih.gov/pubmed/22840315). 
    * Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov.87(11):1006-1009. Pubmedid: [23090887](https://www.ncbi.nlm.nih.gov/pubmed/23090887). 
    * Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May.118(10):2659-2664. Pubmedid: [21956402](https://www.ncbi.nlm.nih.gov/pubmed/21956402). 
    * Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012 Jan.36(1):72-80. Pubmedid: [21782240](https://www.ncbi.nlm.nih.gov/pubmed/21782240). 
    * Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec.120(25):4945-4951. Pubmedid: [22915641](https://www.ncbi.nlm.nih.gov/pubmed/22915641). Pmcid: PMC3525020. 
    * O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM. NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Ne. 2012 Aug.10(8):984-1021. Pubmedid: [22878824](https://www.ncbi.nlm.nih.gov/pubmed/22878824). 
    * Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tr. 2011 Mar.17(3):384-393. Pubmedid: [20655389](https://www.ncbi.nlm.nih.gov/pubmed/20655389). 
    * Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar.17(5):1140-1146. Pubmedid: [21233404](https://www.ncbi.nlm.nih.gov/pubmed/21233404). Pmcid: PMC3049960. 
    * Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar.35(3):301-304. Pubmedid: [21109304](https://www.ncbi.nlm.nih.gov/pubmed/21109304). 
    * Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011 Mar.29(8):979-985. Pubmedid: [21282541](https://www.ncbi.nlm.nih.gov/pubmed/21282541). Pmcid: PMC4520927. 
    * Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun.35(6):e81-e83. Pubmedid: [21232795](https://www.ncbi.nlm.nih.gov/pubmed/21232795). 
    * Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul.118(3):523-528. Pubmedid: [21551228](https://www.ncbi.nlm.nih.gov/pubmed/21551228). Pmcid: PMC3142897. 
    * Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec.25(12):1808-1814. Pubmedid: [21760592](https://www.ncbi.nlm.nih.gov/pubmed/21760592). Pmcid: PMC4576993. 
    * Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteom Clin Appl. 2011 Aug.5(7-8):383-396. Pubmedid: [21656910](https://www.ncbi.nlm.nih.gov/pubmed/21656910). Pmcid: PMC3530891. 
    * Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug.52(8):1528-1536. Pubmedid: [21635204](https://www.ncbi.nlm.nih.gov/pubmed/21635204). Pmcid: PMC4350661. 
    * Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr.117(7):1463-1469. Pubmedid: [21425147](https://www.ncbi.nlm.nih.gov/pubmed/21425147). Pmcid: PMC4545502. 
    * Lancet J, Feldman E, Kolitz J, Tallman M, Hogge DE, Louie A. Phase IIB Randomized Study of CPX-351 Versus Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: An Interim Analysis. Clin Lymphoma Myeloma Leuk. 2010 Jun.10(3):E28. Pubmedid: [20511145](https://www.ncbi.nlm.nih.gov/pubmed/20511145). 
    * Naghashpour M, Lancet J, Moscinski L, Zhang L. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report. Am J Hematol. 2010 Jun.85(6):451-454. Pubmedid: [20513125](https://www.ncbi.nlm.nih.gov/pubmed/20513125). 
    * Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?. Curr Hematol Malig Rep. 2010 Jan.5(1):9-14. Pubmedid: [20425391](https://www.ncbi.nlm.nih.gov/pubmed/20425391). 
    * Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb.45(2):255-260. Pubmedid: [19543327](https://www.ncbi.nlm.nih.gov/pubmed/19543327). 
    * Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Brit J Haematol. 2010 Dec.151(5):430-434. Pubmedid: [21113977](https://www.ncbi.nlm.nih.gov/pubmed/21113977). Pmcid: PMC3058291. 
    * Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010 Apr.24(4):699-705. Pubmedid: [20111068](https://www.ncbi.nlm.nih.gov/pubmed/20111068). 
    * Lancet JE, Karp JE. Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol. 2009 Mar.16(2):105-111. Pubmedid: [19468272](https://www.ncbi.nlm.nih.gov/pubmed/19468272). Pmcid: PMC2861990. 
    * Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res. 2009 Jun.33(6):769-774. Pubmedid: [18976810](https://www.ncbi.nlm.nih.gov/pubmed/18976810). 
    * Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009 Jun.113(26):6533-6540. Pubmedid: [19398716](https://www.ncbi.nlm.nih.gov/pubmed/19398716). 
    * Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res. 2009 Aug.33(8):1055-1061. Pubmedid: [19108889](https://www.ncbi.nlm.nih.gov/pubmed/19108889). 
    * Karp JE, Lancet JE. Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep.2(3):491-500. Pubmedid: [19707379](https://www.ncbi.nlm.nih.gov/pubmed/19707379). Pmcid: PMC2721391. 
    * Lancet JE, Giralt S. Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Ne. 2008 Nov.6(10):1017-1025. Pubmedid: [19176199](https://www.ncbi.nlm.nih.gov/pubmed/19176199). 
    * O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FL. Acute myeloid leukemia. J Natl Compr Canc Ne. 2008 Nov.6(10):962-993. Pubmedid: [19176196](https://www.ncbi.nlm.nih.gov/pubmed/19176196). 
    * Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May.14(10):3077-3082. Pubmedid: [18483374](https://www.ncbi.nlm.nih.gov/pubmed/18483374). Pmcid: PMC3074480. 
    * Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Löwenberg B, Stone RM, De Porre P, Wang Y, Karp JE. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008 Mar.111(5):2589-2596. Pubmedid: [18160667](https://www.ncbi.nlm.nih.gov/pubmed/18160667). 
    * Karp J, Lancet J. Development of farnesyltransferase inhibitors for clinical cancer therapy: focuson hematologic malignancies. Cancer Invest. 2007 Sep.25(6):484-494. Pubmedid: [17882662](https://www.ncbi.nlm.nih.gov/pubmed/17882662). 
    * Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia. 2007 Mar.21(3):586-588. Pubmedid: [17230228](https://www.ncbi.nlm.nih.gov/pubmed/17230228). 
    * Harousseau J, Lancet J, Reiffers J, Lowenberg B, Thomas X, Huguet F, Fenaux P, Zhang S, Rackoff W, De Porre P, Stone R. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007 Jun.109(12):5151-5156. Pubmedid: [17351110](https://www.ncbi.nlm.nih.gov/pubmed/17351110). 
    * Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb.109(4):1387-1394. Pubmedid: [17082323](https://www.ncbi.nlm.nih.gov/pubmed/17082323). Pmcid: PMC1794070. 
    * Raponi M, Harousseau J, Lancet J, Lowenberg B, Stone R, Zhang Y, RackoffW, Wang Y, Atkins D. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2007 Apr.13(7):2254-2260. Pubmedid: [17404110](https://www.ncbi.nlm.nih.gov/pubmed/17404110). 
    * O'Donnell M, Appelbaum F, Baer M, Byrd J, Coutre S, Damon L, Erba H, Estey E, Foran J, Lancet J, Maness L, Maslak P, Millenson M, Moore J, Przepiorka D, Shami P, Smith B, Stone R, Tallman M. Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2006 Jan.4(1):16-36. Pubmedid: [16403402](https://www.ncbi.nlm.nih.gov/pubmed/16403402). 
    * Karp J, Lancet J. Targeting the process of farynesylation for therapy of hematologic malignancies. Curr Mol Med. 2005 Nov.5(7):643-652. Pubmedid: [16305490](https://www.ncbi.nlm.nih.gov/pubmed/16305490). 
    * Lancet J, Karp J. Farnesyl transferase inhibitors in myeloid disorders. Oncology (Williston Park). 2005 Jul.19(8):1043-1049. Pubmedid: [16131046](https://www.ncbi.nlm.nih.gov/pubmed/16131046). 
    * Karp J, Lancet J. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Future Oncol. 2005 Dec.1(6):719-731. Pubmedid: [16556050](https://www.ncbi.nlm.nih.gov/pubmed/16556050). 
    * Liesveld JL, Rosell KE, Lu C, Bechelli J, Phillips G, Lancet JE, Abboud CN. Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology. 2005 Dec.10(6):483-494. Pubmedid: [16321813](https://www.ncbi.nlm.nih.gov/pubmed/16321813). 
    * O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul.28(7):679-689. Pubmedid: [15158089](https://www.ncbi.nlm.nih.gov/pubmed/15158089). 
    * Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 Jan.10(1 Pt 1):88-95. Pubmedid: [14734456](https://www.ncbi.nlm.nih.gov/pubmed/14734456). 
    * Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. Semin Oncol. 2004 Dec.31(6 Suppl 18):59-61. Pubmedid: [15726525](https://www.ncbi.nlm.nih.gov/pubmed/15726525). 
    * Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer. 2004 Aug.4:56. Pubmedid: [15329151](https://www.ncbi.nlm.nih.gov/pubmed/15329151). Pmcid: PMC516036. 
    * Liesveld JL, Lancet JE, Rosell KE, Menon A, Lu C, McNair C, Abboud CN, Rosenblatt JD. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia. 2003 Sep.17(9):1806-1812. Pubmedid: [12970780](https://www.ncbi.nlm.nih.gov/pubmed/12970780). 
    * Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev. 2003 Sep.17(3):123-129. Pubmedid: [12818222](https://www.ncbi.nlm.nih.gov/pubmed/12818222). 
    * Rathnasabapathy R, Lancet J. Management of acute myelogenous leukemia in the elderly. Cancer Control. 2003 Nov.10(6):469-477. Pubmedid: [14652523](https://www.ncbi.nlm.nih.gov/pubmed/14652523). 
    * Komrokji R, Lancet J, Felgar R, Wang N, Bennett J. Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature. Leuk Res. 2003 Jun.27(6):561-566. Pubmedid: [12648517](https://www.ncbi.nlm.nih.gov/pubmed/12648517). 
    * Lancet J, Karp J. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003 Dec.102(12):3880-3889. Pubmedid: [12920034](https://www.ncbi.nlm.nih.gov/pubmed/12920034). 
    * Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, VerstovsekS, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug.102(3):795-801. Pubmedid: [12649163](https://www.ncbi.nlm.nih.gov/pubmed/12649163). 
    * Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr.97(8):1920-1928. Pubmedid: [12673719](https://www.ncbi.nlm.nih.gov/pubmed/12673719). 
    * Lancet J, Rosenblatt J, Karp J. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin Hematol. 2002 Jul.39(3 Suppl 2):31-35. Pubmedid: [12214291](https://www.ncbi.nlm.nih.gov/pubmed/12214291). 
    * Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Tr. 2002.8(12):662-665. Pubmedid: [12523578](https://www.ncbi.nlm.nih.gov/pubmed/12523578). 
    * Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001 Nov.13(6):470-476. Pubmedid: [11673687](https://www.ncbi.nlm.nih.gov/pubmed/11673687). 
    * Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001 Jun.97(11):3361-3369. Pubmedid: [11369625](https://www.ncbi.nlm.nih.gov/pubmed/11369625). 
    * Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging. Clinical interactions. Hematol Oncol Clin North Am. 2000 Feb.14(1):251-267. Pubmedid: [10680081](https://www.ncbi.nlm.nih.gov/pubmed/10680081). 
    * Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998 Aug.22(3):265-271. Pubmedid: [9720740](https://www.ncbi.nlm.nih.gov/pubmed/9720740). 
  * ## Grants
    * Title: North American Star Consortium  
Award Number: 4UM1CA186644-08  
Sponsor: National Cancer Institute (NCI)  
Lancet, J. (PD/PI)


## Find a Researcher Search
Program Select Cancer Biology and Evolution Program Cancer Epidemiology Program Molecular Medicine Program Health Outcomes & Behavior Program Immuno-Oncology Non-Programmatically Aligned
Department Select BioEngineering Biostatistics and Bioinformatics Cancer Epidemiology Metabolism and Physiology Drug Discovery Health Outcomes & Behavior Immunology Integrated Mathematical Oncology Machine Learning Molecular Oncology Tumor Microenvironment and Metastasis
Center of Excellence Select Center for Infection Research in Cancer DeBartolo Family Personalized Medicine Institute Evolutionary Therapy Lung Cancer Center of Excellence Melanoma Research Center of Excellence
Work Group Select Cancer Chemoprevention Research Interest Group Myeloma Systems Medicine Working Group Tobacco Research & Intervention Program
Keyword
Search
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center") [ ![](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-mobile-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center")
Our Mission
To contribute to the prevention and cure of cancer.
[Connect with a Cancer Expert](https://www.moffitt.org/eforms/patientregistrationform/)
[ ![Designated Comprehensive Cancer Center](https://www.moffitt.org/globalassets/images/logos/nci.png) ](https://www.moffitt.org/about-moffitt/nci-designation/?source=footer "Designated Comprehensive Cancer Center") [ ![Florida Health Cancer Center of Excellence](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/moffitt-cancer-center-of-excellence-2.png) ](https://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html "Florida Health Cancer Center of Excellence") [ ![Magnet Recognized](https://www.moffitt.org/globalassets/images/logos/magnet.png) ](https://www.moffitt.org/about-moffitt/medical/nursing/?source=footer "Magnet Recognized") [ ![National Comprehensive Cancer Network](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/nccn.png) ](https://www.nccn.org/patients/ "National Comprehensive Cancer Network")
Careers
    * [Careers at Moffitt](https://www.moffitt.org/careers/)
    * [Search Jobs](https://moffitt-cancer-center-careers.hctsportals.com/)
    * [Training & Education](https://www.moffitt.org/education/)


Emerging Cancer Therapies
    * [CAR T Therapy](https://www.moffitt.org/treatments/immunotherapy/car-t-therapy/)
    * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/)
    * [TIL Therapy](https://www.moffitt.org/treatments/immunotherapy/til-therapy/)


Cancers & Treatments
    * [Cancers We Treat](https://www.moffitt.org/cancers/)
    * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
    * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/)
    * [Treatments We Offer](https://www.moffitt.org/treatments/)


Get Involved
    * [Donate](https://fundraise.moffitt.org/give/563959/#!/donation/checkout)
    * [Volunteer](https://www.moffitt.org/give/get-involved/volunteer-your-time/)
    * [Ways to Give](https://www.moffitt.org/give/ways-to-give/)


Cancer Screening
    * [Head and Neck Cancer Screening](https://www.moffitt.org/diagnostic-services/cancer-screenings/head-and-neck-cancer-screening/)
    * [Lung CT Screening](https://www.moffitt.org/cancers/lung-cancer/lung-cancer-screening-and-surveillance-program/)
    * [Mammogram](https://www.moffitt.org/cancers/breast-cancer/diagnosis/screening/mammogram/)
    * [Skin Cancer Mole Patrol](https://www.moffitt.org/diagnostic-services/cancer-screenings/mole-patrol/)


Patients & Family
    * [Appointments](https://www.moffitt.org/eforms/patientregistrationform/)
    * [Find a Doctor](https://www.moffitt.org/find-a-doctor/)
    * [Insurance & Financial Info](https://www.moffitt.org/patient-family/insurance-financial-information/)
    * [Moffitt Blog for Patients](https://www.moffitt.org/taking-care-of-your-health/)
    * [Patient & Family Resources](https://www.moffitt.org/patient-family/)


About Moffitt
    * [About](https://www.moffitt.org/about-moffitt/)
    * [Community Benefit](https://www.moffitt.org/publications/community-benefit/)
    * [Patient Outcomes](https://www.moffitt.org/about-moffitt/outcomes/)
    * [Research](https://www.moffitt.org/research-science/)


Industry Partnerships
    * [Available Emerging Technologies](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/available-technologies/)
    * [Business of Biotech](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/business-of-biotech/)
    * [Cell Therapy Facility](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/cell-therapy-gene-engineering/)
    * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/)


Resources
    * [Calendar of Events](https://www.moffitt.org/calendar/)
    * [Endeavor](https://www.moffitt.org/endeavor/)
    * [Newsroom](https://www.moffitt.org/newsroom/)
    * [Partnerships](https://www.moffitt.org/about-moffitt/strategic-alliances-and-partnerships/)
    * [Publications](https://www.moffitt.org/publications/)


Call Today
[1-888-663-3488](tel:1-888-663-3488 "Call Today")
[ ](https://www.facebook.com/MoffittCancerCenter "Facebook") [ ](https://twitter.com/MoffittNews "Twitter") [ ](https://www.instagram.com/moffittcancercenter/ "Instagram") [ ](https://www.youtube.com/user/MoffittNews "YouTube")
[ Getting Here ](https://www.moffitt.org/locations-directions/) [ Patient Portal ](https://my.moffitt.org/?source=footer&_ga=2.263078223.2128654650.1660063894-1522311918.1659049215) [ Refer a Patient ](https://www.moffitt.org/eforms/referapatient/) [ Provider Portal ](https://rpp.moffitt.org/) [ Staff Login ](https://hlmconnect.moffitt.org/dana-na/auth/url_default/welcome.cgi?source=footer&_ga=2.192849257.2128654650.1660063894-1522311918.1659049215)
  * [Privacy Policy](https://www.moffitt.org/legal-statements-and-policies/privacy-policy/)
  * [Terms & Conditions](https://www.moffitt.org/terms-conditions/ "Terms & Condition")
  * [Unsubscribe](https://www.moffitt.org/eforms/unsubscribe/ "Unsubscribe")
  * [State Nonprofit Disclosures](https://www.moffitt.org/globalassets/pdfs/footer/state-registration-for-web.pdf "State Nonprofit Disclosures")
  * [Donor Privacy](https://www.moffitt.org/give/donor-privacy/ "Donor Privacy")
  * [Notice of Privacy Practices](https://www.moffitt.org/legal-statements-and-policies/notice-of-privacy-practices/ "Notice of Privacy Practices")
  * [Visitor Policy](https://www.moffitt.org/globalassets/pdfs/patient--family/preparing-for-your-appointment/visitation-and-family-presence-policy.pdf "Visitor Policy")
  * [Moffitt Masking Policy](https://www.moffitt.org/globalassets/pdfs/footer/ic-085-moffitt-masking-policy.pdf)
  * [Price Transparency](https://eforms.moffitt.org/Moffittcancercenter_standardcharges/593238634_H.-Lee-Moffitt-Cancer-Center-and-Research-Institute-Hospital,-Inc._standardcharges.json)
  * [Sitemap](https://www.moffitt.org/sitemap.xml)


©Copyright 2025 Moffitt Cancer Center
Discover More
  * [Individualized Cancer Treatment in Florida](https://moffitt.org/patient-family/)
  * [Cancer Second Opinion Appointment in Florida](https://moffitt.org/diagnostic-services/second-opinion/)
  * [Cancer Healthcare Professionals in Florida](https://moffitt.org/for-healthcare-professionals/)


### Cambiar el idioma
Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al [1-888-663-3488](tel:1-888-663-3488).
Gracias.
[Cancel | Cancelar](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [OK](https://www.moffitt.org/research-science/researchers/jeffrey-lancet)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Search
Menu
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-31)
  * [Research](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Training & Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)
  * [Give](https://www.moffitt.org/research-science/researchers/jeffrey-lancet) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)


Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/jeffrey-lancet/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/jeffrey-lancet/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate")
[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)[Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)
  * [ Cancers ](https://www.moffitt.org/cancers/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-5)
  * [ Treatments ](https://www.moffitt.org/treatments/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-7)
  * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-9)
  * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-11)


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)[Cancers](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)
  * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
  * [Acute Myelogenous Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myelogenous Leukemia \(AML\)")
  * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
  * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
  * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
  * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
  * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
  * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
  * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
  * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
  * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
  * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
  * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
  * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
  * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
  * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
  * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
  * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
  * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
  * [Chronic Myelogenous Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myelogenous Leukemia \(CML\)")
  * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
  * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
  * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
  * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
  * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
  * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
  * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
  * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
  * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
  * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
  * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
  * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
  * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
  * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
  * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
  * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
  * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
  * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
  * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
  * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
  * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
  * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
  * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
  * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
  * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
  * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
  * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
  * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
  * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
  * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
  * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
  * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
  * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
  * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
  * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
  * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
  * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
  * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
  * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
  * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
  * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
  * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
  * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
  * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
  * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
  * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
  * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
  * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
  * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
  * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
  * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
  * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
  * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
  * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
  * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
  * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
  * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
  * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
  * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
  * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
  * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)[Treatments](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)
  * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
  * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
  * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
  * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
  * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
  * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
  * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
  * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
  * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
  * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
  * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
  * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
  * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
  * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
  * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
  * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
  * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
  * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
  * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
  * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
  * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
  * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)[Clinical Trials](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)
  * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
  * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
  * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
  * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
  * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
  * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)[Diagnostic Services](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-3)
  * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
  * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
  * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
  * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
  * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
  * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)[Patients & Families](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)
  * [ Patient & Family ](https://www.moffitt.org/patient-family/)
  * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-15)
  * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-17)
  * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-19)
  * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-21)
  * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-23)
  * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-25)
  * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-27)
  * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-29)


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Preparing For Your Appointment](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
  * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
  * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
  * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
  * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
  * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
  * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
  * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
  * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
  * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
  * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
  * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
  * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Insurance & Financial Information](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
  * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
  * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
  * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
  * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
  * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
  * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
  * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
  * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
  * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Programs & Support Services](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
  * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
  * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
  * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
  * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
  * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
  * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
  * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
  * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Patient and Family Centered Care](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
  * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
  * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
  * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
  * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
  * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Cancer Survivorship](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[International Patient Services](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
  * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
  * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
  * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Moffitt Virtual Care](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
  * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
  * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
  * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)[Inspiring Stories](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-13)
  * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
  * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
  * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
  * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
  * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
  * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
  * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
  * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
  * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
  * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
  * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
  * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
  * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
  * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
  * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
  * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
  * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
  * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
  * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
  * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
  * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
  * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
  * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
  * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
  * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
  * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
  * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
  * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
  * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
  * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
  * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
  * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
  * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
  * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
  * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
  * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
  * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
  * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
  * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
  * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
  * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
  * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
  * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
  * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
  * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
  * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
  * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
  * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
  * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
  * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
  * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
  * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
  * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
  * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
  * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
  * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
  * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
  * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
  * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
  * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
  * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
  * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
  * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
  * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
  * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
  * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
  * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
  * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
  * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
  * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
  * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
  * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
  * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
  * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
  * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
  * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
  * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
  * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
  * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
  * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
  * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
  * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
  * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
  * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
  * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
  * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
  * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
  * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
  * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
  * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
  * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
  * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
  * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
  * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
  * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
  * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
  * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
  * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
  * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
  * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
  * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
  * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
  * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
  * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
  * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
  * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
  * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
  * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
  * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
  * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)[For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)
  * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
  * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-33)
  * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
  * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-35)


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-31)[Clinical Programs and Services](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-31)
  * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
  * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
  * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
  * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
  * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
  * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
  * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
  * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
  * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
  * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
  * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
  * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
  * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
  * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
  * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
  * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
  * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
  * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
  * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
  * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
  * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
  * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
  * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
  * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
  * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
  * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-31)[Continuing Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-31)
  * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
  * [Multidisciplinary Programs](https://www.moffitt.org/for-healthcare-professionals/continuing-education/multidisciplinary-programs/ "Multidisciplinary Programs")
  * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)[Research](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)
  * [ Research Science ](https://www.moffitt.org/research-science/)
  * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-39)
  * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-41)
  * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-43)
  * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-45)
  * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-47)
  * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-49)
  * [ Administration ](https://www.moffitt.org/research-science/administration/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-51)


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Research Programs](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
  * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
  * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
  * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
  * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Divisions and Departments](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
  * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
  * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
  * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
  * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Centers and Institutes](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
  * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Community Outreach and Engagement](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
  * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
  * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
  * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
  * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
  * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
  * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Shared Resources](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
  * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
  * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
  * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
  * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
  * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
  * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
  * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
  * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
  * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
  * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
  * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
  * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Academic and Industry Partnerships](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
  * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)[Administration](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-37)
  * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)[Training & Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)
  * [ Education ](https://www.moffitt.org/education/)
  * [ Medical Education ](https://www.moffitt.org/education/medical-education/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-55)
  * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-57)
  * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-59)
  * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-61)
  * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)[Medical Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)
  * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
  * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
  * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)[Research Education and Training](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)
  * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
  * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
  * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
  * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
  * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
  * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
  * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
  * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)[Nursing Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)
  * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
  * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
  * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
  * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
  * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)[Health Professional Education](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-53)
  * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
  * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
  * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
  * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
  * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
  * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
  * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
  * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
  * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
  * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
  * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
  * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
  * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
  * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
  * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
  * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
  * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
  * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
  * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
  * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
  * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
  * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
  * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
  * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)[Give](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-1)
  * [ Give ](https://www.moffitt.org/give/)
  * [ Why Give? ](https://www.moffitt.org/give/why-give/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-65)
  * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-67)
  * [ Get Involved ](https://www.moffitt.org/give/get-involved/) [](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-69)


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)[Why Give?](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)
  * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
  * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
  * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
  * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
  * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
  * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)[Ways to Give](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)
  * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
  * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
  * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
  * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
  * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
  * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
  * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
  * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
  * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
  * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)[Get Involved](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#mm-63)
  * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
  * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
  * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
  * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
  * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
  * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
  * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")


[](https://www.moffitt.org/research-science/researchers/jeffrey-lancet#page)
